Protagonist (PTGX) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The EV/EBITDA multiple reflects the valuation dynamics of Protagonist Therapeutics (PTGX), with the latest value recorded as 24.92. A network of global laboratories ensures the logistics of peptide components. Growth prospects rely on the success of rusfertide and strategic partnerships, although financial stability remains constrained by R&D expenditures and the risk of clinical trial failures.
protagonist-inc.com - analytical breakdowns and key metrics (PTGX)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Protagonist Therapeutics|PTGX - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Protagonist|PTGX - Company Cumulative Debt|Debt to Book Capitalization Ratio Protagonist Corp|PTGX - Long-Term Liabilities|Company Short-Term Debt Protagonist Therapeutics|Quick Liquidity protagonist-inc.com
- business earnings and investment ratios data:
PTGX - Company Net Income|Future Profit Protagonist Therapeutics|PTGX - Market Price to Net Income Ratio|Forward P/E Multiple Protagonist Therapeutics|PTGX - PEG Multiple|EV/EBITDA Multiple Protagonist Corp|PTGX - Operating profit before depreciation charges|Earnings per share for the last twelve months Protagonist Therapeutics|PTGX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months protagonist-inc.com|PTGX - Earnings per share growth this year|Earnings growth forecast for next year Protagonist Therapeutics
Initial company analysis:PTGX (Protagonist Therapeutics Inc)
For the investor, the asset quality of Protagonist Therapeutics (PTGX) is determined by its ability to capitalize on peptide developments and payments from J&J. By analyzing the company's trend EV/EBITDA level, we assess the total enterprise value relative to operating income, which clarifies the extent to which the market is overvaluing Phase 3 potential given the existing cash reserves and debt load.
Direct competitors
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Immunovant (IMVT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Kiniksa Pharmaceuticals, Ltd.|Enterprise Value to EBITDA Ratio GRFS|EV/EBITDA Multiple Adaptive Biotechnologies Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Celldex Therapeutics (CLDX)|auriniapharma.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BCRX (BioCryst Pharmaceuticals)|Vera Therapeutics Inc (VERA) - Company Value to EBITDA|DNTH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio PHVS|abcellera.com (ABCL) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|tourmalinebio.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Precigen|Company Value to EBITDA Pharming Group NV PHAR|Enterprise Value to EBITDA Ratio NKTR (Nektar)|Enterprise Value to Operating Income Before Depreciation Ratio UPB|EV/EBITDA Multiple ZBIO (Zenas Biopharma Inc)|EV/EBITDA Multiple immunome.com IMNM|Gossamer Bio - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple KalVista Pharma (KALV)|Septerna Corp (SEPN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Pieris Corp (PVLA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Savara Inc.|Enterprise Value to Operating Income Before Depreciation RIGL (rigel.com)|EV/EBITDA Multiple ANAB|Total Company Value to Operating Income Before Depreciation Ratio Astria Therapeutics Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization enGene Bio ENGN|Total Company Value to Operating Income Before Depreciation Ratio rapt.com (RAPT)|JBIO: Enterprise Value to EBITDA Ratio|aclaristx.com - Enterprise Value to Operating Income Before Depreciation Ratio|KYTX (Kyverna Therapeutics, Inc.) - Enterprise Value to EBITDA Ratio|Tiziana Life Sciences Ltd. - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio CABA|VTYX (Ventyx Biosciences, Inc) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple THTX|AVTX (avalotx.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ELDN (Eledon Pharmaceuticals, Inc.)|Agenus, Inc. (AGEN) - Company Value to EBITDA|CLYM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation ZURA (zurabio.com)|ATYR: EV/EBITDA Multiple|Adagene Inc. (ADAG) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ImageneBio|Shattuck Therapeutics - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple EQ|CNTB - Company Value to EBITDA|Immunic - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Atara Biotherapeutics, Inc. ATRA|IFRX: Enterprise Value to EBITDA Ratio|X4 Pharmaceuticals Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|ACET: EV/EBITDA Multiple|CELU - Total Company Value to Operating Income Before Depreciation Ratio|INMB (INmune Bio, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio barinthusbio.com (BRNS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kezar Life Sciences, Inc. (KZR)|Total Company Value to Operating Income Before Depreciation Ratio SAB Biotherapeutics Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Akari Therapeutics plc AKTX|ENLV (Enlivex Therapeutics Ltd) - Company Value to Operating Income Before Depreciation Ratio|QTTB: Enterprise Value to EBITDA Ratio|geovax.com - Enterprise Value to Operating Income Before Depreciation Ratio|EDSA: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple iBio Inc IBIO|Enterprise Value to EBITDA Ratio CARM|Enterprise Value to Operating Income Before Depreciation XTLB (XTL Bio)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bolt Biotherapeutics (BOLT)|HCWB: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple APVO (Aptevo Therapeutics Inc.)|Business Value to Operating Income Before Depreciation AIM|Aditxt Corp - EV/EBITDA Multiple|GRI - EV/EBITDA Multiple|XORTX Therapeutics Inc. (XRTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|reshapelifesciences.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Revelation Biosciences, Inc.|Enterprise Value to EBITDA Ratio Indaptus Therapeutics Inc (INDP)|EV/EBITDA Multiple SCNI|EV/EBITDA Multiple calcimedica.com (CALI)|Affimed N.V. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ALLK|HOOKIPA - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio IGM Biosciences, Inc. IGMS|iTeos (ITOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Ocean Biomedical Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TC Biopharm|Enterprise Value to EBITDA Ratio thirdharmonicbio.com (THRD)
